HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to...

Related Keywords

United States , France , Luis Sanay , Kumar Budur , Exchange Commission , Zynerba Pharmaceuticals , Prnewswire Harmony Biosciences Holdings Inc , Drug Administration , Paragon Biosciences , Us Food Drug Administration , Biosciences Holdings , Orphan Drug Designation , Chief Medical Officer , Full Prescribing Information , Harmony Biosciences , Plymouth Meeting , Private Securities Litigation Reform Act , Annual Report , Biosciences Media Contact , Biosciences Investor Contact ,